Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
46.73
+0.71 (1.54%)
Mar 6, 2026, 10:42 AM EST - Market open
KNSA Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for KNSA stock have an average target of 55.29, with a low estimate of 50 and a high estimate of 62. The average target predicts an increase of 18.32% from the current stock price of 46.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KNSA stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 5 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $53 | Buy | Maintains | $50 → $53 | +13.42% | Feb 25, 2026 |
| Wedbush | Wedbush | Buy Maintains $50 → $53 | Buy | Maintains | $50 → $53 | +13.42% | Feb 25, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $62 | Strong Buy | Initiates | $62 | +32.68% | Feb 19, 2026 |
| Wedbush | Wedbush | Buy Maintains $48 → $50 | Buy | Maintains | $48 → $50 | +7.00% | Jan 13, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $45 → $55 | Strong Buy | Maintains | $45 → $55 | +17.70% | Oct 29, 2025 |
Financial Forecast
Revenue This Year
935.11M
from 677.56M
Increased by 38.01%
Revenue Next Year
1.10B
from 935.11M
Increased by 17.42%
EPS This Year
1.24
from 0.75
Increased by 65.24%
EPS Next Year
1.75
from 1.24
Increased by 41.40%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 971.1M | 1.2B | |||
| Avg | 935.1M | 1.1B | |||
| Low | 888.9M | 1.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 43.3% | 26.9% | |||
| Avg | 38.0% | 17.4% | |||
| Low | 31.2% | 9.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.49 | 2.40 | |||
| Avg | 1.24 | 1.75 | |||
| Low | 0.80 | 1.09 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 98.8% | 94.0% | |||
| Avg | 65.2% | 41.4% | |||
| Low | 7.1% | -12.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.